Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y₁₂ receptor inhibitors.

Antonino MJ, Jeong YH, Tantry US, Bliden KP, Gurbel PA.

Expert Rev Cardiovasc Ther. 2012 Aug;10(8):1011-22. doi: 10.1586/erc.12.1. Review.

PMID:
23030291
2.

Modern antiplatelet agents in coronary artery disease.

Power RF, Hynes BG, Moran D, Yagoub H, Kiernan G, Ruggiero NJ, Kiernan TJ.

Expert Rev Cardiovasc Ther. 2012 Oct;10(10):1261-72. doi: 10.1586/erc.12.127. Review.

PMID:
23190065
3.

Ticagrelor for the treatment of arterial thrombosis.

Gurbel PA, Kereiakes DJ, Tantry US.

Expert Opin Pharmacother. 2010 Sep;11(13):2251-9. doi: 10.1517/14656566.2010.511175. Review.

PMID:
20707759
4.

A critical appraisal of the functional evolution of P2Y12 antagonists as antiplatelet drugs.

Fayaz SM, Rajanikant GK.

Curr Pharm Des. 2012;18(12):1625-34. Review.

PMID:
22360514
5.

Functional testing methods for the antiplatelet effect of P2Y12 receptor antagonists.

Price MJ, Barker CM.

Biomark Med. 2011 Feb;5(1):43-51. doi: 10.2217/bmm.11.1. Review.

PMID:
21319964
6.

Oral antiplatelet therapy for acute coronary syndromes: aspirin, P2Y12 inhibition and thrombin receptor antagonists.

Bailey AL, Campbell CL.

Curr Drug Targets. 2011 Nov;12(12):1805-12. Review.

PMID:
21718239
7.

The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.

Bernlochner I, Byrne RA, Kastrati A, Sibbing D.

Expert Rev Cardiovasc Ther. 2011 Aug;9(8):999-1014. doi: 10.1586/erc.11.80. Review.

PMID:
21878045
8.

The role of antiplatelet therapy in the secondary prevention of coronary artery disease.

Behan MW, Chew DP, Aylward PE.

Curr Opin Cardiol. 2010 Jul;25(4):321-8. doi: 10.1097/HCO.0b013e328338f7b5. Review.

PMID:
20386440
9.

P2Y12 receptor inhibitors for secondary prevention of ischemic stroke.

Liu F, Tantry US, Gurbel PA.

Expert Opin Pharmacother. 2015 Jun;16(8):1149-65. doi: 10.1517/14656566.2015.1035256. Epub 2015 Apr 14. Review.

PMID:
25873127
10.

Personalized antiplatelet therapy for coronary artery disease patients: is this the future?

Bonello L, Lemesle G, De Labriolle A, Barragan P, Camoin-Jau L, Paganelli F.

Expert Rev Cardiovasc Ther. 2009 Dec;7(12):1525-32. doi: 10.1586/erc.09.146. Review.

PMID:
19954314
11.

Clopidogrel in coronary artery disease: update 2012.

Huber K.

Adv Cardiol. 2012;47:31-8. doi: 10.1159/000338051. Epub 2012 Aug 9. Review.

PMID:
22906901
12.

[Recent advances on the studies of the platelet's inhibition and aggregation. State of the art of new P2Y12 antagonists].

Cattaneo GJ, Podda GM, Cattaneo M.

Recenti Prog Med. 2011 Apr;102(4):150-5. doi: 10.1701/624.7286. Review. Italian.

PMID:
21572491
13.

Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.

Tan GM, Lam YY, Yan BP.

Cardiovasc Ther. 2012 Aug;30(4):e167-73. doi: 10.1111/j.1755-5922.2011.00262.x. Epub 2011 Jul 31. Review.

PMID:
21883998
14.

Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.

Packard KA, Campbell JA, Knezevich JT, Davis EM.

Pharmacotherapy. 2012 Mar;32(3):244-73. doi: 10.1002/j.1875-9114.2012.01021.x. Review.

PMID:
22392457
15.

Current status and prospects of antiplatelet therapy in percutaneous coronary intervention in Japan: focus on adenosine diphosphate receptor inhibitors.

Ogawa H, Hokimoto S, Kaikita K, Yamamoto K, Chitose T, Ono T, Tsujita K.

J Cardiol. 2011 Jul;58(1):6-17. doi: 10.1016/j.jjcc.2011.03.002. Epub 2011 Apr 29. Review.

16.

Pharmacogenetics of the antiplatelet effect of aspirin.

Würtz M, Kristensen SD, Hvas AM, Grove EL.

Curr Pharm Des. 2012;18(33):5294-308. Review.

PMID:
22724416
17.

Current antiplatelet agents: place in therapy and role of genetic testing.

Yang E.

J Thromb Thrombolysis. 2015 Apr;39(3):328-36. doi: 10.1007/s11239-015-1195-5. Review.

PMID:
25700561
18.

Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents.

Höchtl T, Tentzeris I, Schrör K, Huber K.

Fundam Clin Pharmacol. 2012 Feb;26(1):2-10. doi: 10.1111/j.1472-8206.2011.00985.x. Epub 2011 Aug 10. Review.

PMID:
21831128
19.

[The role of direct-acting P2Y12 inhibitors in acute coronary syndrome].

Buriakina TA, Zateĭshchikov DA.

Kardiologiia. 2012;52(4):74-9. Review. Russian.

PMID:
22839520
20.

P2Y12 receptor antagonists in acute coronary syndrome: clinical implications of pharmacologic and pharmacogenetic differences.

Singh M, Adigopula S, Ahmad N, Arora R, Khosla S.

Recent Pat Cardiovasc Drug Discov. 2011 Sep;6(3):207-14. Review.

PMID:
21861826

Supplemental Content

Support Center